Yu, Diana H.
Shafiq, Majid
Batra, Hitesh
Johnson, Marla
Griscom, Bailey
Chamberlin, Janna
Lofaro, Lori R.
Huang, Jing
Bulman, William A.
Kennedy, Giulia C.
Yarmus, Lonny B.
Lee, Hans J.
Feller-Kopman, David
Funding for this research was provided by:
Veracyte
Article History
Received: 10 February 2022
Revised: 9 September 2022
Accepted: 28 September 2022
First Online: 24 November 2022
Declarations
:
: The Percepta Registry was a multi-center prospective study that included patients with lung nodules who underwent clinically indicated diagnostic bronchoscopy at participating medical centers in the U.S. Ethics review and approval was obtained by each institution before enrollment and written informed consent was obtained from all patients. All methods were carried out in accordance with relevant guidelines and regulations or declaration of Helsinki.
: The site name, corresponding Institutional Review Board (IRB), and the IRB number for each site participating in the Percepta Registry is shown below.Table removed
: Not applicable.
: MJ, BG, JC, LRL, JH, WAB, and GCK are employed by Veracyte, Inc. LBY, HJL, and DFK have received honoraria for speaking engagements and consulting on behalf of Veracyte, Inc. DHY received reimbursement for travel and honraria for consulting for Veracyte, Inc. The remaining authors (MS and HB) declare no competing interests.